Activation of Transferrin Receptor 1 by c-Myc Enhances Cellular Proliferation and Tumorigenesis

ABSTRACT Overexpression of transferrin receptor 1 (TFRC1), a major mediator of iron uptake in mammalian cells, is a common feature of human malignancies. Therapeutic strategies designed to interfere with tumor iron metabolism have targeted TFRC1. The c-Myc oncogenic transcription factor stimulates proliferation and growth by activating thousands of target genes. Here we demonstrate that TFRC1 is a critical downstream target of c-Myc. Using in vitro and in vivo models of B-cell lymphoma, we show that TFRC1 expression is activated by c-Myc. Chromatin immunoprecipitation experiments reveal that c-Myc directly binds a conserved region of TFRC1. In light of these findings, we sought to determine whether TFRC1 is required for c-Myc-mediated cellular proliferation and cell size control. TFRC1 inhibition decreases cellular proliferation and results in G1 arrest without affecting cell size. Consistent with these findings, expression profiling reveals that TFRC1 depletion alters expression of genes that regulate the cell cycle. Furthermore, enforced TFRC1 expression confers a growth advantage to cells and significantly enhances the rate of c-Myc-mediated tumor formation in vivo. These findings provide a molecular basis for increased TFRC1 expression in human tumors, illuminate the role of TFRC1 in the c-Myc target gene network, and support strategies that target TFRC1 for cancer therapy.

[1]  M. Eilers,et al.  Transcriptional regulation and transformation by Myc proteins , 2005, Nature Reviews Molecular Cell Biology.

[2]  Kathryn A. O’Donnell,et al.  Myc Stimulates Nuclearly Encoded Mitochondrial Genes and Mitochondrial Biogenesis , 2005, Molecular and Cellular Biology.

[3]  J. Tobias,et al.  Inactivation of Myc in murine two-hit B lymphomas causes dormancy with elevated levels of interleukin 10 receptor and CD20: implications for adjuvant therapies. , 2005, Cancer research.

[4]  Kathryn A. O’Donnell,et al.  c-Myc-regulated microRNAs modulate E2F1 expression , 2005, Nature.

[5]  D Remondini,et al.  Targeting c-Myc-activated genes with a correlation method: detection of global changes in large gene expression network dynamics. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Richard A. Woo,et al.  Activated oncogenes promote and cooperate with chromosomal instability for neoplastic transformation. , 2004, Genes & development.

[7]  R. Eisenman,et al.  Myc A Weapon of Mass Destruction , 2004, Cell.

[8]  Thomas Walz,et al.  Structure of the Human Transferrin Receptor-Transferrin Complex , 2004, Cell.

[9]  T. Barrette,et al.  ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.

[10]  V. Perry,et al.  Characterization of the Murine Nramp1 Promoter , 2003, Journal of Biological Chemistry.

[11]  Douglas A. Hosack,et al.  Identifying biological themes within lists of genes with EASE , 2003, Genome Biology.

[12]  Kathryn A. O’Donnell,et al.  An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets , 2003, Genome Biology.

[13]  T. Graeber,et al.  Myc-driven murine prostate cancer shares molecular features with human prostate tumors. , 2003, Cancer cell.

[14]  Michael Q. Zhang,et al.  A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Andrea Cocito,et al.  Genomic targets of the human c-Myc protein. , 2003, Genes & development.

[16]  B. Edgar,et al.  Genomic binding by the Drosophila Myc, Max, Mad/Mnt transcription factor network. , 2003, Genes & development.

[17]  Chi V. Dang,et al.  A strategy for identifying transcription factor binding sites reveals two classes of genomic c-Myc target sites , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  John M Sedivy,et al.  A Large Scale Genetic Analysis of c-Myc-regulated Gene Expression Patterns* 210 , 2003, The Journal of Biological Chemistry.

[19]  L. Penn,et al.  Functional analysis of the N-terminal domain of the Myc oncoprotein , 2003, Oncogene.

[20]  J. Monroe,et al.  Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway. , 2003, Blood.

[21]  Stella Pelengaris,et al.  c-MYC: more than just a matter of life and death , 2002, Nature Reviews Cancer.

[22]  M. Cole,et al.  A Functional Screen for Myc-Responsive Genes Reveals Serine Hydroxymethyltransferase, a Major Source of the One-Carbon Unit for Cell Metabolism , 2002, Molecular and Cellular Biology.

[23]  David Botstein,et al.  Transformation of follicular lymphoma to diffuse large-cell lymphoma: Alternative patterns with increased or decreased expression of c-myc and its regulated genes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[24]  D. Richardson Iron chelators as therapeutic agents for the treatment of cancer. , 2002, Critical reviews in oncology/hematology.

[25]  Chi V. Dang,et al.  The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[26]  A. Orth,et al.  Large-scale analysis of the human and mouse transcriptomes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Duonan Yu,et al.  A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis , 2002, Oncogene.

[28]  V. Perry,et al.  c-Myc represses the murine Nramp1 promoter. , 2001, Biochemical Society transactions.

[29]  D. Richardson Therapeutic potential of iron chelators in cancer therapy. , 2002, Advances in experimental medicine and biology.

[30]  L. Penn,et al.  The myc oncogene: MarvelouslY Complex. , 2002, Advances in cancer research.

[31]  K. Zeller,et al.  Characterization of Nucleophosmin (B23) as a Myc Target by Scanning Chromatin Immunoprecipitation* , 2001, The Journal of Biological Chemistry.

[32]  T. Tuschl,et al.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.

[33]  R. Kennett,et al.  Inhibition of N-myc expression and induction of apoptosis by iron chelation in human neuroblastoma cells. , 2001, Cancer research.

[34]  U. Weidle,et al.  The transcriptional program of a human B cell line in response to Myc. , 2001, Nucleic acids research.

[35]  B. Kempkes,et al.  Cell cycle activation by c‐myc in a Burkitt lymphoma model cell line , 2000, International journal of cancer.

[36]  R. DePinho,et al.  Cellular Senescence Minireview Mitotic Clock or Culture Shock? , 2000, Cell.

[37]  E. Lander,et al.  Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[39]  R. DePinho,et al.  Cellular senescence: mitotic clock or culture shock? , 2000, Cell.

[40]  R. Eisenman,et al.  c-Myc enhances protein synthesis and cell size during B lymphocyte development. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[41]  M. Cole,et al.  The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation , 1999, Oncogene.

[42]  Kou-Juey Wu,et al.  Coordinated regulation of iron-controlling genes, H-ferritin and IRP2, by c-MYC. , 1999, Science.

[43]  Chi V. Dang,et al.  c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism , 1999, Molecular and Cellular Biology.

[44]  P. Farnham,et al.  c-Myc target gene specificity is determined by a post-DNAbinding mechanism. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Sedivy,et al.  Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[46]  R. Eisenman,et al.  Myc target genes. , 1997, Trends in biochemical sciences.

[47]  R. Eisenman,et al.  Myc‐Max heterodimers activate a DEAD box gene and interact with multiple E box‐related sites in vivo. , 1996, The EMBO journal.

[48]  R. Weiner The mechanism of 67Ga localization in malignant disease. , 1996, Nuclear medicine and biology.

[49]  G. Wahl,et al.  A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. , 1996, Genes & development.

[50]  J. Sedivy,et al.  Effects of c-myc expression on cell cycle progression , 1994, Molecular and cellular biology.

[51]  Kevin M Smith,et al.  Effects of anti-transferrin receptor antibodies on the growth of neoplastic cells. , 1992, Pathobiology : journal of immunopathology, molecular and cellular biology.

[52]  J. Delville,et al.  CD71 phenotype and the value of gallium imaging in lymphomas , 1991, American journal of hematology.

[53]  L. Kühn The transferrin receptor: a key function in iron metabolism. , 1989, Schweizerische medizinische Wochenschrift.

[54]  Didier Picard,et al.  Chimaeras of Myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells , 1989, Nature.

[55]  D. Becton,et al.  Deferoxamine inhibition of human neuroblastoma viability and proliferation. , 1988, Cancer research.

[56]  M. Schwab,et al.  Neoplastic transformation by the human gene N-myc , 1987, Molecular and cellular biology.

[57]  H. Varmus,et al.  Definition of regions in human c-myc that are involved in transformation and nuclear localization , 1987, Molecular and cellular biology.

[58]  J. Blatt,et al.  Antineuroblastoma activity of desferoxamine in human cell lines. , 1987, Cancer research.

[59]  L. Neckers,et al.  Transferrin receptor expression and the control of cell growth. , 1986, Cancer investigation.

[60]  P. Seligman,et al.  Regulation of transferrin receptor expression on human leukemic cells during proliferation and induction of differentiation. Effects of gallium and dimethylsulfoxide. , 1983, The Journal of clinical investigation.

[61]  I. Trowbridge,et al.  Effects of anti‐transferrin receptor antibodies on growth of normal and malignant myeloid cells , 1983, International journal of cancer.

[62]  D. Mason,et al.  Transferrin receptors in human tissues: their distribution and possible clinical relevance. , 1983, Journal of clinical pathology.

[63]  I. Christensen,et al.  A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. , 1983, Cytometry.

[64]  P. Cresswell,et al.  Modulation of cell surface iron transferrin receptors by cellular density and state of activation. , 1979, Journal of supramolecular structure.